CHIMERIC
THERAPEUTICS

APPENDIX 4C

Quarter Ended 30 September 2026

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **29 October 2026**

QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDING 30 SEPTEMBER 2026

Sydney, Australia, 29 October 2026: Chimeric Therapeutics Limited (ASX: CHM, "Chimeric" or the "Company"), an Australian cell therapy company, provides a summary of its activities for the quarter ended 30 September 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Clinical Trial Updates

CHM CDH17 Phase 1/2 trial enrolment and dosing ceased following safety review

During the Quarter, Chimeric ceased enrolment and dosing in its Phase 1/2 clinical trial of CHM-2101, its autologous CDH17 CAR-T cell therapy for advanced gastrointestinal cancers, following a determination by the independent Safety Monitoring Committee (**SMC**).

In July, the Company reported interim data from two patients treated at Dose Level 3, comprising 450 million CAR-T cells. The preliminary results showed tumour shrinkage ranging from 17% to 40% in individual lesions, with the two patients maintaining stable disease for six months and four months respectively, as assessed under RECIST 1.1 criteria.

In August, the Company reported that a second patient among the four treated at Dose Level 3 had experienced non-fatal dose-limiting toxicities. The most recently treated patient experienced Grade 3 adverse events including gastrointestinal fistula, rectal pain and pelvic infection, which the SMC determined were probably related to CHM-2101.

Under the study's 3+3 dose-escalation design, the SMC determined that Dose Level 3 was unsafe and that no further patients should be treated at this dose level. Adverse events across the study also met the protocol-defined trigger for stopping enrolment. Accordingly, enrolment and dosing were stopped in accordance with the study protocol, and the Company made the necessary notification to the US Food and Drug Administration (**FDA**).

The Company's preliminary analysis of the 14 patients treated in the study identified anti-tumour activity, including reductions in target lesions and tumour markers, and persistence of CHM-2101 CAR-T cells for up to 15 months. However, the dose levels required to achieve activity were not tolerated within an acceptable safety margin using the current autologous product. The Board therefore determined not to progress CHM-2101 in its current form.

Remaining patients will be followed up as required by the study protocol, primarily through the external Contract Research Organisation.

In vivo CDH17 development pathway

Following the cessation of enrolment and dosing, Chimeric outlined a proposed development pathway focused on an in vivo approach to CDH17, informed by the clinical findings from CHM-2101.

In vivo delivery involves administering the CAR construct directly to the patient, rather than manufacturing an autologous cell product outside the body. The Company believes this approach could reduce manufacturing cost and complexity and allow a different dosing and safety profile for the same target.

Chimeric's existing licence from the University of Pennsylvania extends to in vivo delivery of CDH17, and no additional licence is required to commence this development programme.

This programme currently remains at a preclinical stage and no development candidate had been selected. Initial animal feasibility work is planned, with commencement and continuation of the programme subject to securing additional funding.

CHM CORE-NK

Subsequent to the end of the Quarter, Chimeric confirmed that the investigator-led CORE-NK study remained ongoing and required no funding or support from the Company.

Corporate Updates

Strategic review

On 1 July 2026, Chimeric appointed Hawkesbury Partners Pty Limited as independent financial adviser to undertake a structured review of the strategic options available to the Company, with the objective of maximising shareholder value. The review's scope included strategic partnerships and funding, licensing arrangements, co-development agreements, mergers, asset sales and alternative capital structures.

As part of this process, the Company has explored opportunities to sell, out-license or partner the CHM CDH17 asset and programme, including CHM-2101. A number of pharmaceutical companies were approached. As disclosed in August 2026, no interest in proceeding with a potential transaction had been received at that stage. The Company indicated its intention to re-engage with potential partners as the in vivo pathway advanced.

Cost reductions

Following the cessation of CHM-2101 enrolment and dosing, Chimeric implemented reductions across headcount, manufacturing and clinical trial-related expenditure. These measures were estimated to reduce annualised expenditure by approximately $4 million, following initial termination costs.

Subsequent to the end of the Quarter, the Company confirmed that its US operations had been significantly reduced, including activities associated with the wind-down of the Phase 1/2 clinical study and a reduction in US-based employees. Further cost reductions included downsizing the Board.

Board changes

On 6 July 2026, Mr Eric Sullivan retired from the Board for personal reasons, effective immediately.

Subsequent to the end of the Quarter, on 1 October 2026, Dr Bradley Glover and Dr Lesley Russell retired as directors. Chief Executive Officer Dr Rebecca McQualter was appointed to the Board as Managing Director, with no other change to her employment terms or remuneration, and Mr Phillip Hains was appointed Interim Chairman.

With these changes, the Board comprises Mr Phillip Hains, Professor Miles Prince and Dr Rebecca McQualter. The full Board has assumed the functions of the Audit and Risk Committee until further notice.

Creditor negotiations and potential recapitalisation

During the Quarter, Chimeric advised that it intended to negotiate with creditors, including the provider of its convertible note facility, to reduce its liabilities and negative net asset position, while also pursuing additional funding. The Company is seeking to settle valid and agreed liabilities on an unconditional basis, through binding deeds of settlement, at a level able to be satisfied from its current financial resources. The outcome and timing of negotiations remain uncertain.

The Company has received interest in recapitalising the Company, subject to sustainable changes to its balance sheet structure. There is no certainty that a recapitalisation will proceed, or as to its terms or timing.

FY2026 financial statements and suspension from trading

Subsequent to the end of the Quarter, on 1 October 2026, Chimeric advised that its securities had been suspended from trading under ASX Listing Rule 17.5 because its FY2026 financial statements had not been lodged by the 30 September 2026 deadline.

Release of the financial statements was delayed pending the negotiation of unconditional agreements with creditors and a recapitalisation. The Company advised that it expected its securities to remain suspended until the audited financial statements were lodged and ASX was satisfied that the requirements for reinstatement had been met.

The Preliminary Final Report lodged on 31 August 2026 reported a deficiency of net assets of approximately $7.7 million. The FY2026 financial statements are expected to include a material uncertainty in relation to going concern. The Company's ability to continue as a going concern depends on additional funding and the outcome of creditor negotiations.

Financial Update and Appendix 4C

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

The Company had $1.35 million in cash and cash equivalents at 30 September 2026, increasing from $0.80 million at 30 June 2026.

The net cash outflow from Operating Activities during the Quarter was $1.68 million with 70% of operating outflows relating to staff costs, and research and development.

The net financing inflows for the quarter was $2.24 million which consists of $1.62 million from entering into a loan agreement to advance the Company's anticipated FY26 Research and Development Tax Incentive and $0.65 million received from issue of convertible debt securities less transaction costs.

In accordance with Listing Rule 4.7C, payments to related parties and their associates included in item 6.1 of the Appendix 4C were $nil, as there were no directors' fees paid to executive and non-executive directors during the September quarter in the normal course of business at commercial rates, excluding reimbursement of out-of-pocket expenses. Following the September quarter clinical wind-down, December quarter outflows will be limited to essential operations, a minimal R&D programme to preserve the value of the CDH17 assets, and any settlement payments agreed with creditors.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, an Australian clinical stage cell therapy company, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's team of cell therapy pioneers is focused on the discovery, development, and commercialisation of innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies.

For more information visit www.chimerictherapeutics.com or follow us on LinkedIn at www.linkedin.com/company/chimeric-therapeutics.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.

Contact

Investors
Dr Rebecca McQualter
Managing Director and Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	-
1.2	Payments for (inclusive of GST)		
	(a) research and development	(627)	(627)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(558)	(558)
	(f) administration and corporate costs	(534)	(534)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	7	7
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	29	29
1.9	**Net cash from / (used in) operating activities**	**(1,683)**	**(1,683)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Payments of license fee liabilities)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	650	650
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(32)	(32)
3.5	Proceeds from borrowings	1,623	1,623
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – repayment of debt facility	-	-
3.10	**Net cash from / (used in) financing activities**	**2,241**	**2,241**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	800	800
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,683)	(1,683)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,241	2,241
4.5	Effect of movement in exchange rates on cash held	(11)	(11)
4.6	**Cash and cash equivalents at end of period**	**1,347**	**1,347**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,347	800
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,347**	**800**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,683)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,347
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**1,347**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.80

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No. Following the September quarter clinical wind-down, December quarter outflows will be limited to essential operations, a minimal R&D programme to preserve the value of the CDH17 assets, and any settlement payments agreed with creditors.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes. The Company is negotiating binding settlements with its creditors as the first step to a recapitalisation. It has received interest in recapitalising the Company, subject to sustainable changes to its balance sheet structure. The outcome and timing remain uncertain.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes, subject to the outcome and timing of the steps in 8.6.2. The Company's immediate objectives are to settle with creditors, complete its audited FY2026 financial statements, have its securities reinstated to quotation and recapitalise. The FY2026 financial statements are expected to include a material uncertainty related to going concern.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 October 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

+61 3 9824 5254
info@chimerictherapeutics.com

Chimeric Therapeutics Limited
ACN 638 835 828

ASX: CHM